TR200003844T2 - Epotilon türevleri, sentezleri ve kullanımları - Google Patents

Epotilon türevleri, sentezleri ve kullanımları

Info

Publication number
TR200003844T2
TR200003844T2 TR2000/03844T TR200003844T TR200003844T2 TR 200003844 T2 TR200003844 T2 TR 200003844T2 TR 2000/03844 T TR2000/03844 T TR 2000/03844T TR 200003844 T TR200003844 T TR 200003844T TR 200003844 T2 TR200003844 T2 TR 200003844T2
Authority
TR
Turkey
Prior art keywords
unit
units
group
single bond
present
Prior art date
Application number
TR2000/03844T
Other languages
English (en)
Turkish (tr)
Inventor
Costa Nicolaou Kyriacos
Paul King Nigel
Raymond Verschoyle Finlay Maurice
He Yun
Roschangar Frank
Vourloumis Dionisios
Vallberg Hans
Bigot Antony
Original Assignee
Novartis Ag
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, The Scripps Research Institute filed Critical Novartis Ag
Publication of TR200003844T2 publication Critical patent/TR200003844T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TR2000/03844T 1998-06-22 1999-06-21 Epotilon türevleri, sentezleri ve kullanımları TR200003844T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/102,602 US6380394B1 (en) 1996-12-13 1998-06-22 Epothilone analogs

Publications (1)

Publication Number Publication Date
TR200003844T2 true TR200003844T2 (tr) 2001-04-20

Family

ID=22290705

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03844T TR200003844T2 (tr) 1998-06-22 1999-06-21 Epotilon türevleri, sentezleri ve kullanımları

Country Status (27)

Country Link
US (3) US6380394B1 (enExample)
EP (2) EP1089998B1 (enExample)
JP (1) JP4681732B2 (enExample)
KR (3) KR20080045298A (enExample)
CN (1) CN1192031C (enExample)
AT (1) ATE343573T1 (enExample)
AU (1) AU757854B2 (enExample)
BR (1) BR9911420A (enExample)
CA (1) CA2334342C (enExample)
CY (1) CY1105863T1 (enExample)
CZ (1) CZ301783B6 (enExample)
DE (1) DE69933767T2 (enExample)
DK (1) DK1089998T3 (enExample)
ES (1) ES2273502T3 (enExample)
HU (1) HUP0102711A3 (enExample)
ID (1) ID28210A (enExample)
IL (3) IL139784A0 (enExample)
MX (1) MXPA00012443A (enExample)
NO (1) NO328417B1 (enExample)
NZ (1) NZ508622A (enExample)
PL (1) PL197648B1 (enExample)
PT (1) PT1089998E (enExample)
RU (1) RU2227142C2 (enExample)
SK (2) SK287864B6 (enExample)
TR (1) TR200003844T2 (enExample)
WO (1) WO1999067252A2 (enExample)
ZA (1) ZA200007059B (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
PL193229B1 (pl) * 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
DE19820599A1 (de) * 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
SK287200B6 (sk) * 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CN1348370A (zh) 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
AU2508201A (en) * 1999-11-24 2001-06-04 Basf Aktiengesellschaft Fungicidal melithiazole derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
AU2001291876C1 (en) * 2000-09-22 2006-11-23 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Triazolo-epothilones
JP2005500974A (ja) * 2000-10-13 2005-01-13 ザ ユニバーシテイ オブ ミシシッピー エポシロン類及び関連類似体の合成
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
RU2003126171A (ru) 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
EP1368030A1 (en) 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
MXPA03007466A (es) * 2001-02-27 2003-12-08 Gbf Ges F R Biotechnologische Degradacion de epotilonas y epotilonas substituidas con etileno.
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2002098868A1 (en) * 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Epothilone derivatives
BR0212107A (pt) * 2001-08-23 2004-08-24 Novartis Ag Análogos da ciclopropil e da ciclobutil epotilona
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
DK1441714T3 (da) * 2001-10-25 2008-03-31 Novartis Ag Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor
WO2003048774A1 (en) * 2001-12-07 2003-06-12 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
NZ533940A (en) 2002-01-14 2007-06-29 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003266961A1 (en) * 2002-08-02 2004-02-25 Novartis Ag Epothilone derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO2004018478A2 (en) * 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
GB0221312D0 (en) * 2002-09-13 2002-10-23 Novartis Ag Organic compounds
RS20050235A (sr) 2002-09-23 2007-06-04 Bristol Myers Squibb Company, Postupci za pripremanje,izolaciju i prečišćavanje epotilona b i kristalne strukture epotilona b dobijene primenom x-zraka
DE60310975T2 (de) * 2002-10-15 2007-07-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Verwendung von epothilone zur behandlung hyperparathyreoidismus
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP1856255A4 (en) 2005-02-11 2010-01-27 Univ Southern California PROCESS FOR EXPRESSING PROTEINS VIA DISULPHIDE BRIDGES
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US7893268B2 (en) * 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
CN101360494A (zh) * 2005-11-22 2009-02-04 斯克里普斯研究学院 高效埃博霉素的化学合成
US7653731B2 (en) * 2006-02-24 2010-01-26 Microsoft Corporation Management of connections to external data
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
JP2010511408A (ja) 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
WO2008098216A2 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US8435983B2 (en) * 2007-03-23 2013-05-07 The University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
MX2011000144A (es) * 2008-07-03 2011-02-24 Pharma Mar Sa Compuestos antitumorales.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CN103442737B (zh) 2011-01-20 2017-03-29 得克萨斯系统大学董事会 Mri标记、递送和提取系统及其制造方法和用途
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
EP2793949B1 (en) 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2014116594A1 (en) * 2013-01-23 2014-07-31 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
EP3371176A4 (en) * 2015-10-16 2019-09-04 William Marsh Rice University EPOTHILON ANALOGUE, SYNTHESIS METHOD, TREATMENT METHOD AND MEDICAMENT CONJUGATE THEREFOR
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW221441B (enExample) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
PL193229B1 (pl) 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

Also Published As

Publication number Publication date
US6380394B1 (en) 2002-04-30
PT1089998E (pt) 2007-01-31
PL345327A1 (en) 2001-12-17
US7579366B2 (en) 2009-08-25
EP1089998B1 (en) 2006-10-25
CZ301783B6 (cs) 2010-06-23
EP1741715A1 (en) 2007-01-10
AU4774899A (en) 2000-01-10
CN1192031C (zh) 2005-03-09
IL139784A0 (en) 2002-02-10
ID28210A (id) 2001-05-10
JP2002518504A (ja) 2002-06-25
KR20080045298A (ko) 2008-05-22
JP4681732B2 (ja) 2011-05-11
HUP0102711A2 (hu) 2001-12-28
CA2334342A1 (en) 1999-12-29
CA2334342C (en) 2012-07-17
US20030203938A1 (en) 2003-10-30
ATE343573T1 (de) 2006-11-15
DK1089998T3 (da) 2007-01-15
EP1089998A2 (en) 2001-04-11
CZ20004769A3 (cs) 2001-07-11
WO1999067252A2 (en) 1999-12-29
KR20090066332A (ko) 2009-06-23
US6531497B1 (en) 2003-03-11
HK1038358A1 (en) 2002-03-15
NO328417B1 (no) 2010-02-15
CN1306531A (zh) 2001-08-01
BR9911420A (pt) 2001-03-20
WO1999067252A3 (en) 2000-03-16
CY1105863T1 (el) 2011-02-02
NZ508622A (en) 2003-07-25
DE69933767T2 (de) 2007-09-13
RU2227142C2 (ru) 2004-04-20
IL182744A (en) 2010-05-17
MXPA00012443A (es) 2004-12-03
ZA200007059B (en) 2002-01-30
SK287864B6 (sk) 2012-02-03
KR20010083060A (ko) 2001-08-31
IL139784A (en) 2010-05-17
KR100864742B1 (ko) 2008-10-22
AU757854B2 (en) 2003-03-06
IL182744A0 (en) 2007-07-24
ES2273502T3 (es) 2007-05-01
DE69933767D1 (de) 2006-12-07
NO20006378D0 (no) 2000-12-14
HUP0102711A3 (en) 2002-09-30
SK285647B6 (sk) 2007-05-03
PL197648B1 (pl) 2008-04-30
SK19712000A3 (sk) 2001-09-11
NO20006378L (no) 2001-02-21

Similar Documents

Publication Publication Date Title
TR200003844T2 (tr) Epotilon türevleri, sentezleri ve kullanımları
TW357174B (en) Synergistic stabilizer mixture
TR199800602A2 (xx) Dithiolan t�revleri, haz�rlanmalar� ve terap�tik etkileri.
NZ331319A (en) Cyclic amine derivatives that are CCR-3 receptor (chemokine receptor) antagonists, compositions containing them and methods for their use (to combat eosinophil induced diseases).
NZ507735A (en) Indole derivatives useful for treating malignant and other diseases caused by pathological cell proliferation
TW358808B (en) Morpholine derivatives, preparation thereof and pharmaceutical composition containing the same
MY106250A (en) Azolylmethylcyclopentane benzylidene fungicide.
AU6950301A (en) Amino alcohol derivatives
IE893294L (en) Piperidinyl benzimidazoles
HUP0001796A2 (hu) Dipeptid-benzamidinek mint kininogenáz inhibitorok, és a vegyületeket tartalmazó gyógyszerkészítmények
DE69609325D1 (de) Derivate des radicicols
TR199902897T2 (xx) S�v� benz-izo-kuinolin t�revleri.
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
TR200200070T2 (tr) Titanyum-türevli bileşikler, bunların hazırlanması ve kullanımı.
GB2311780A (en) Piperazine-2,5-dione derivatives as modulators of multidrug resistance
FR2677023B1 (fr) Derives de coumarine hydrosolubles, leur preparation et leur utilisation comme substrat d'enzyme.
NZ238033A (en) 1-indanone- or 1-tetralone-2'-amidinohydrazone derivatives and pharmaceutical compositions thereof
GB8921792D0 (en) New compositions of matter
MX9603199A (es) Antagonistas de receptores a endotelina.
TW334428B (en) Novel benzodiazepine derivatives
TW372955B (en) Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
TR199700481A2 (xx) Sefem ve izooksafem t�revlerinin haz�rlanmas�.
CA2074039A1 (en) Antihypertensive combination
ATE115572T1 (de) N-2-chlorbenzyl-2-oxo- und n-2-chlorbenzyl-2,2,- dioxo-1,2,3-oxathiazolidinderivate, ihre herstellung und ihre verwendung in der synthese von thieno(3,2-c>pyridinderivaten.
ATE105565T1 (de) Pradimicinderivate.